Global Drug-Resistant Tuberculosis Treatment Market
Global Drug-Resistant Tuberculosis Treatment Market

Drug-Resistant Tuberculosis Treatment Comprehensive Study by Type (Amoxicillin/Clavulanate, Bedaquiline, Carbapenems with Clavulanic Acid, Clofazimine, Cycloserine, Delamanid, Ethambutol, Others), Application (Hospital, Clinics, Others), Disease Type (Multidrug-Resistant TB (MDR TB), Extensively Drug-resistant TB (XDR TB)), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, Others), Treatment Type (First-Line Anti-TB Drugs, Second-Line Anti-TB Drugs, Others) Players and Region - Global Market Outlook to 2026

Drug-Resistant Tuberculosis Treatment Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Aug 2021 Edition 247 Pages 217 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Industry Background:
Tuberculosis (TB) is a disease caused by bacteria that is transmitted through the air from one person to another. When the medicines used to treat TB are overuse or mishandled, such as when people do not finish the full course of TB medication, drug-resistant TB can develop. Special laboratory techniques that screen the bacteria for drug sensitivity or discover resistance patterns can be used to detect drug resistance. With the introduction of fast molecular diagnostic tests, new and repurposed medicines, the treatment and management of DR-TB have progressed substantially in the last decade.This growth is primarily driven by Increase in Patient Population Suffering from Drug-Resistant Tuberculosis and Increased R&D by Research Institute and Pharma Company.

Globally, a noticeable market trend is evident Advancement of Meta-Analytic Approaches Methodology. Major Players, such as Sanofi (France), Novartis AG (Switzerland), Endo International plc (Ireland), CMP Pharma (United States), STI Pharma LLC (United States), Akorn Incorporated (United States), Lupin (India), Johnson & Johnson Services Inc. (United States), Macleods Pharmaceuticals Ltd (India), Pfizer Inc (United States), Hikma Pharmaceuticals PLC (United Kingdom) and Lannett (United States) etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.

Key Developments in the Market:
On 15 July 2021, the process of a new, safe, and affordable treatment solution for Anti Tuberculosis science 30 partners from 13 countries has officially launch UNIT4TB. The aim is to speed up and enhance clinical trials of existing and novel medication combinations and highly effective TB treatment regimens for drug-resistant and drug-sensitive TB. The rise of multidrug-resistant tuberculosis (MDR-TB) is widely recognized as a public health threat, and it has spurred renewed interest and funding in anti-TB medication research. Despite the increased effort in the sector, there is still a lack of an integrated approach to TB medication development.
On 14 Aug 2019, TB Alliance received USFDA approval for Pretomanid, a New Treatment for Highly Drug-Resistant Forms of Tuberculosis. The new drug was approved as part of a three-drug, six-month, all-oral regimen for the treatment of people with extensively drug-resistant TB (XDR-TB) or multidrug-resistant TB (MDR-TB) who are treatment-intolerant or non-responsive under the Limited Population Pathway for Antibacterial and Antifungal Drugs.

Regulatory Insights:
ďAs per WHO Guideline, when developing longer MDR-TB regimens, injectables are no longer considered priority medications. Capreomycin and kanamycin are no longer recommended antibiotics. For the most part, patients choose oral regimens. All prolonged regimens with other medications graded by a relative balance of benefits to risks should include fluoroquinolones, bedaquiline, and linezolid. The majority of regimens should comprise at least four medicines that are expected to be successful in the first six months, followed by three drugs. Longer MDR-TB regimens should last 18 to 20 months, with the length varying based on the patient's response.Ē

Market Drivers
  • Increase in Patient Population Suffering from Drug-Resistant Tuberculosis
  • Increased R&D by Research Institute and Pharma Company

Market Trend
  • Advancement of Meta-Analytic Approaches Methodology

Restraints
  • Complex treatment and Expensive with Less Cure and High Mortality Rate

Opportunities
Large Support from Government and Regulatory Bodies
Challenges
Lack of Skilled Researchers and Infrastructure in Developing Countries

AMA Research follow a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcase the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyse the products and services offered by multiple players competing to increase their market share and presence.

Customization in the Report
AMA Research features not only specific market forecasts, but also include significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints
- New Entrants into the Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis

Against this Challenging Backdrop, Drug-Resistant Tuberculosis Treatment Study Sheds Light on
— The Drug-Resistant Tuberculosis Treatment Market status quo and key characteristics. To end this, Analyst at AMA organize and took survey of the Drug-Resistant Tuberculosis Treatment industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Drug-Resistant Tuberculosis Treatment industry is heading and what are the top priorities. Insights are drawn from financial analysis, the survey and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold value they currently claim, or capture the new addressable opportunity.

Frequently Asked Questions (FAQ):

1. What are the years considered in the Drug-Resistant Tuberculosis Treatment Market?
Historical year: 2016-2020; Base year: 2020; Forecast period: to 2026

2. Who are the key players profiled in the Drug-Resistant Tuberculosis Treatment Market?
Companies that are profiled in Global Drug-Resistant Tuberculosis Treatment Market are Sanofi (France), Novartis AG (Switzerland), Endo International plc (Ireland), CMP Pharma (United States), STI Pharma LLC (United States), Akorn Incorporated (United States), Lupin (India), Johnson & Johnson Services Inc. (United States), Macleods Pharmaceuticals Ltd (India), Pfizer Inc (United States), Hikma Pharmaceuticals PLC (United Kingdom) and Lannett (United States) etc.

3. What is Drug-Resistant Tuberculosis Treatment Market?
Tuberculosis (TB) is a disease caused by bacteria that is transmitted through the air from one person to another. When the medicines used to treat TB are overuse or mishandled, such as when people do not finish the full course of TB medication, drug-resistant TB can develop. Special laboratory techniques that screen the bacteria for drug sensitivity or discover resistance patterns can be used to detect drug resistance. With the introduction of fast molecular diagnostic tests, new and repurposed medicines, the treatment and management of DR-TB have progressed substantially in the last decade.
Report Objectives / Segmentation Covered
By Type
  • Amoxicillin/Clavulanate
  • Bedaquiline
  • Carbapenems with Clavulanic Acid
  • Clofazimine
  • Cycloserine
  • Delamanid
  • Ethambutol
  • Others
By Application
  • Hospital
  • Clinics
  • Others
By Disease Type
  • Multidrug-Resistant TB (MDR TB)
  • Extensively Drug-resistant TB (XDR TB)

By Distribution Channel
  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy
  • Others

By Treatment Type
  • First-Line Anti-TB Drugs
  • Second-Line Anti-TB Drugs
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increase in Patient Population Suffering from Drug-Resistant Tuberculosis
      • 3.2.2. Increased R&D by Research Institute and Pharma Company
    • 3.3. Market Challenges
      • 3.3.1. Lack of Skilled Researchers and Infrastructure in Developing Countries
    • 3.4. Market Trends
      • 3.4.1. Advancement of Meta-Analytic Approaches Methodology
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Drug-Resistant Tuberculosis Treatment, by Type, Application, Disease Type, Distribution Channel, Treatment Type and Region (value, volume and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Drug-Resistant Tuberculosis Treatment (Value)
      • 5.2.1. Global Drug-Resistant Tuberculosis Treatment by: Type (Value)
        • 5.2.1.1. Amoxicillin/Clavulanate
        • 5.2.1.2. Bedaquiline
        • 5.2.1.3. Carbapenems with Clavulanic Acid
        • 5.2.1.4. Clofazimine
        • 5.2.1.5. Cycloserine
        • 5.2.1.6. Delamanid
        • 5.2.1.7. Ethambutol
        • 5.2.1.8. Others
      • 5.2.2. Global Drug-Resistant Tuberculosis Treatment by: Application (Value)
        • 5.2.2.1. Hospital
        • 5.2.2.2. Clinics
        • 5.2.2.3. Others
      • 5.2.3. Global Drug-Resistant Tuberculosis Treatment by: Disease Type (Value)
        • 5.2.3.1. Multidrug-Resistant TB (MDR TB)
        • 5.2.3.2. Extensively Drug-resistant TB (XDR TB)
      • 5.2.4. Global Drug-Resistant Tuberculosis Treatment by: Distribution Channel (Value)
        • 5.2.4.1. Hospital Pharmacy
        • 5.2.4.2. Online Pharmacy
        • 5.2.4.3. Retail Pharmacy
        • 5.2.4.4. Others
      • 5.2.5. Global Drug-Resistant Tuberculosis Treatment by: Treatment Type (Value)
        • 5.2.5.1. First-Line Anti-TB Drugs
        • 5.2.5.2. Second-Line Anti-TB Drugs
        • 5.2.5.3. Others
      • 5.2.6. Global Drug-Resistant Tuberculosis Treatment Region
        • 5.2.6.1. South America
          • 5.2.6.1.1. Brazil
          • 5.2.6.1.2. Argentina
          • 5.2.6.1.3. Rest of South America
        • 5.2.6.2. Asia Pacific
          • 5.2.6.2.1. China
          • 5.2.6.2.2. Japan
          • 5.2.6.2.3. India
          • 5.2.6.2.4. South Korea
          • 5.2.6.2.5. Taiwan
          • 5.2.6.2.6. Australia
          • 5.2.6.2.7. Rest of Asia-Pacific
        • 5.2.6.3. Europe
          • 5.2.6.3.1. Germany
          • 5.2.6.3.2. France
          • 5.2.6.3.3. Italy
          • 5.2.6.3.4. United Kingdom
          • 5.2.6.3.5. Netherlands
          • 5.2.6.3.6. Rest of Europe
        • 5.2.6.4. MEA
          • 5.2.6.4.1. Middle East
          • 5.2.6.4.2. Africa
        • 5.2.6.5. North America
          • 5.2.6.5.1. United States
          • 5.2.6.5.2. Canada
          • 5.2.6.5.3. Mexico
    • 5.3. Global Drug-Resistant Tuberculosis Treatment (Volume)
      • 5.3.1. Global Drug-Resistant Tuberculosis Treatment by: Type (Volume)
        • 5.3.1.1. Amoxicillin/Clavulanate
        • 5.3.1.2. Bedaquiline
        • 5.3.1.3. Carbapenems with Clavulanic Acid
        • 5.3.1.4. Clofazimine
        • 5.3.1.5. Cycloserine
        • 5.3.1.6. Delamanid
        • 5.3.1.7. Ethambutol
        • 5.3.1.8. Others
      • 5.3.2. Global Drug-Resistant Tuberculosis Treatment by: Application (Volume)
        • 5.3.2.1. Hospital
        • 5.3.2.2. Clinics
        • 5.3.2.3. Others
      • 5.3.3. Global Drug-Resistant Tuberculosis Treatment by: Disease Type (Volume)
        • 5.3.3.1. Multidrug-Resistant TB (MDR TB)
        • 5.3.3.2. Extensively Drug-resistant TB (XDR TB)
      • 5.3.4. Global Drug-Resistant Tuberculosis Treatment by: Distribution Channel (Volume)
        • 5.3.4.1. Hospital Pharmacy
        • 5.3.4.2. Online Pharmacy
        • 5.3.4.3. Retail Pharmacy
        • 5.3.4.4. Others
      • 5.3.5. Global Drug-Resistant Tuberculosis Treatment by: Treatment Type (Volume)
        • 5.3.5.1. First-Line Anti-TB Drugs
        • 5.3.5.2. Second-Line Anti-TB Drugs
        • 5.3.5.3. Others
      • 5.3.6. Global Drug-Resistant Tuberculosis Treatment Region
        • 5.3.6.1. South America
          • 5.3.6.1.1. Brazil
          • 5.3.6.1.2. Argentina
          • 5.3.6.1.3. Rest of South America
        • 5.3.6.2. Asia Pacific
          • 5.3.6.2.1. China
          • 5.3.6.2.2. Japan
          • 5.3.6.2.3. India
          • 5.3.6.2.4. South Korea
          • 5.3.6.2.5. Taiwan
          • 5.3.6.2.6. Australia
          • 5.3.6.2.7. Rest of Asia-Pacific
        • 5.3.6.3. Europe
          • 5.3.6.3.1. Germany
          • 5.3.6.3.2. France
          • 5.3.6.3.3. Italy
          • 5.3.6.3.4. United Kingdom
          • 5.3.6.3.5. Netherlands
          • 5.3.6.3.6. Rest of Europe
        • 5.3.6.4. MEA
          • 5.3.6.4.1. Middle East
          • 5.3.6.4.2. Africa
        • 5.3.6.5. North America
          • 5.3.6.5.1. United States
          • 5.3.6.5.2. Canada
          • 5.3.6.5.3. Mexico
    • 5.4. Global Drug-Resistant Tuberculosis Treatment (Price)
      • 5.4.1. Global Drug-Resistant Tuberculosis Treatment by: Type (Price)
  • 6. Drug-Resistant Tuberculosis Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Sanofi (France)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Novartis AG (Switzerland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Endo International plc (Ireland)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. CMP Pharma (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. STI Pharma LLC (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Akorn Incorporated (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Lupin (India)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Johnson & Johnson Services Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Macleods Pharmaceuticals Ltd (India)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Pfizer Inc (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Hikma Pharmaceuticals PLC (United Kingdom)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Lannett (United States)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
  • 7. Global Drug-Resistant Tuberculosis Treatment Sale, by Type, Application, Disease Type, Distribution Channel, Treatment Type and Region (value, volume and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Drug-Resistant Tuberculosis Treatment (Value)
      • 7.2.1. Global Drug-Resistant Tuberculosis Treatment by: Type (Value)
        • 7.2.1.1. Amoxicillin/Clavulanate
        • 7.2.1.2. Bedaquiline
        • 7.2.1.3. Carbapenems with Clavulanic Acid
        • 7.2.1.4. Clofazimine
        • 7.2.1.5. Cycloserine
        • 7.2.1.6. Delamanid
        • 7.2.1.7. Ethambutol
        • 7.2.1.8. Others
      • 7.2.2. Global Drug-Resistant Tuberculosis Treatment by: Application (Value)
        • 7.2.2.1. Hospital
        • 7.2.2.2. Clinics
        • 7.2.2.3. Others
      • 7.2.3. Global Drug-Resistant Tuberculosis Treatment by: Disease Type (Value)
        • 7.2.3.1. Multidrug-Resistant TB (MDR TB)
        • 7.2.3.2. Extensively Drug-resistant TB (XDR TB)
      • 7.2.4. Global Drug-Resistant Tuberculosis Treatment by: Distribution Channel (Value)
        • 7.2.4.1. Hospital Pharmacy
        • 7.2.4.2. Online Pharmacy
        • 7.2.4.3. Retail Pharmacy
        • 7.2.4.4. Others
      • 7.2.5. Global Drug-Resistant Tuberculosis Treatment by: Treatment Type (Value)
        • 7.2.5.1. First-Line Anti-TB Drugs
        • 7.2.5.2. Second-Line Anti-TB Drugs
        • 7.2.5.3. Others
      • 7.2.6. Global Drug-Resistant Tuberculosis Treatment Region
        • 7.2.6.1. South America
          • 7.2.6.1.1. Brazil
          • 7.2.6.1.2. Argentina
          • 7.2.6.1.3. Rest of South America
        • 7.2.6.2. Asia Pacific
          • 7.2.6.2.1. China
          • 7.2.6.2.2. Japan
          • 7.2.6.2.3. India
          • 7.2.6.2.4. South Korea
          • 7.2.6.2.5. Taiwan
          • 7.2.6.2.6. Australia
          • 7.2.6.2.7. Rest of Asia-Pacific
        • 7.2.6.3. Europe
          • 7.2.6.3.1. Germany
          • 7.2.6.3.2. France
          • 7.2.6.3.3. Italy
          • 7.2.6.3.4. United Kingdom
          • 7.2.6.3.5. Netherlands
          • 7.2.6.3.6. Rest of Europe
        • 7.2.6.4. MEA
          • 7.2.6.4.1. Middle East
          • 7.2.6.4.2. Africa
        • 7.2.6.5. North America
          • 7.2.6.5.1. United States
          • 7.2.6.5.2. Canada
          • 7.2.6.5.3. Mexico
    • 7.3. Global Drug-Resistant Tuberculosis Treatment (Volume)
      • 7.3.1. Global Drug-Resistant Tuberculosis Treatment by: Type (Volume)
        • 7.3.1.1. Amoxicillin/Clavulanate
        • 7.3.1.2. Bedaquiline
        • 7.3.1.3. Carbapenems with Clavulanic Acid
        • 7.3.1.4. Clofazimine
        • 7.3.1.5. Cycloserine
        • 7.3.1.6. Delamanid
        • 7.3.1.7. Ethambutol
        • 7.3.1.8. Others
      • 7.3.2. Global Drug-Resistant Tuberculosis Treatment by: Application (Volume)
        • 7.3.2.1. Hospital
        • 7.3.2.2. Clinics
        • 7.3.2.3. Others
      • 7.3.3. Global Drug-Resistant Tuberculosis Treatment by: Disease Type (Volume)
        • 7.3.3.1. Multidrug-Resistant TB (MDR TB)
        • 7.3.3.2. Extensively Drug-resistant TB (XDR TB)
      • 7.3.4. Global Drug-Resistant Tuberculosis Treatment by: Distribution Channel (Volume)
        • 7.3.4.1. Hospital Pharmacy
        • 7.3.4.2. Online Pharmacy
        • 7.3.4.3. Retail Pharmacy
        • 7.3.4.4. Others
      • 7.3.5. Global Drug-Resistant Tuberculosis Treatment by: Treatment Type (Volume)
        • 7.3.5.1. First-Line Anti-TB Drugs
        • 7.3.5.2. Second-Line Anti-TB Drugs
        • 7.3.5.3. Others
      • 7.3.6. Global Drug-Resistant Tuberculosis Treatment Region
        • 7.3.6.1. South America
          • 7.3.6.1.1. Brazil
          • 7.3.6.1.2. Argentina
          • 7.3.6.1.3. Rest of South America
        • 7.3.6.2. Asia Pacific
          • 7.3.6.2.1. China
          • 7.3.6.2.2. Japan
          • 7.3.6.2.3. India
          • 7.3.6.2.4. South Korea
          • 7.3.6.2.5. Taiwan
          • 7.3.6.2.6. Australia
          • 7.3.6.2.7. Rest of Asia-Pacific
        • 7.3.6.3. Europe
          • 7.3.6.3.1. Germany
          • 7.3.6.3.2. France
          • 7.3.6.3.3. Italy
          • 7.3.6.3.4. United Kingdom
          • 7.3.6.3.5. Netherlands
          • 7.3.6.3.6. Rest of Europe
        • 7.3.6.4. MEA
          • 7.3.6.4.1. Middle East
          • 7.3.6.4.2. Africa
        • 7.3.6.5. North America
          • 7.3.6.5.1. United States
          • 7.3.6.5.2. Canada
          • 7.3.6.5.3. Mexico
    • 7.4. Global Drug-Resistant Tuberculosis Treatment (Price)
      • 7.4.1. Global Drug-Resistant Tuberculosis Treatment by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Drug-Resistant Tuberculosis Treatment: by Type(USD Million)
  • Table 2. Drug-Resistant Tuberculosis Treatment Amoxicillin/Clavulanate , by Region USD Million (2015-2020)
  • Table 3. Drug-Resistant Tuberculosis Treatment Bedaquiline , by Region USD Million (2015-2020)
  • Table 4. Drug-Resistant Tuberculosis Treatment Carbapenems with Clavulanic Acid , by Region USD Million (2015-2020)
  • Table 5. Drug-Resistant Tuberculosis Treatment Clofazimine , by Region USD Million (2015-2020)
  • Table 6. Drug-Resistant Tuberculosis Treatment Cycloserine , by Region USD Million (2015-2020)
  • Table 7. Drug-Resistant Tuberculosis Treatment Delamanid , by Region USD Million (2015-2020)
  • Table 8. Drug-Resistant Tuberculosis Treatment Ethambutol , by Region USD Million (2015-2020)
  • Table 9. Drug-Resistant Tuberculosis Treatment Others , by Region USD Million (2015-2020)
  • Table 10. Drug-Resistant Tuberculosis Treatment: by Application(USD Million)
  • Table 11. Drug-Resistant Tuberculosis Treatment Hospital , by Region USD Million (2015-2020)
  • Table 12. Drug-Resistant Tuberculosis Treatment Clinics , by Region USD Million (2015-2020)
  • Table 13. Drug-Resistant Tuberculosis Treatment Others , by Region USD Million (2015-2020)
  • Table 14. Drug-Resistant Tuberculosis Treatment: by Disease Type(USD Million)
  • Table 15. Drug-Resistant Tuberculosis Treatment Multidrug-Resistant TB (MDR TB) , by Region USD Million (2015-2020)
  • Table 16. Drug-Resistant Tuberculosis Treatment Extensively Drug-resistant TB (XDR TB) , by Region USD Million (2015-2020)
  • Table 17. Drug-Resistant Tuberculosis Treatment: by Distribution Channel(USD Million)
  • Table 18. Drug-Resistant Tuberculosis Treatment Hospital Pharmacy , by Region USD Million (2015-2020)
  • Table 19. Drug-Resistant Tuberculosis Treatment Online Pharmacy , by Region USD Million (2015-2020)
  • Table 20. Drug-Resistant Tuberculosis Treatment Retail Pharmacy , by Region USD Million (2015-2020)
  • Table 21. Drug-Resistant Tuberculosis Treatment Others , by Region USD Million (2015-2020)
  • Table 22. Drug-Resistant Tuberculosis Treatment: by Treatment Type(USD Million)
  • Table 23. Drug-Resistant Tuberculosis Treatment First-Line Anti-TB Drugs , by Region USD Million (2015-2020)
  • Table 24. Drug-Resistant Tuberculosis Treatment Second-Line Anti-TB Drugs , by Region USD Million (2015-2020)
  • Table 25. Drug-Resistant Tuberculosis Treatment Others , by Region USD Million (2015-2020)
  • Table 26. South America Drug-Resistant Tuberculosis Treatment, by Country USD Million (2015-2020)
  • Table 27. South America Drug-Resistant Tuberculosis Treatment, by Type USD Million (2015-2020)
  • Table 28. South America Drug-Resistant Tuberculosis Treatment, by Application USD Million (2015-2020)
  • Table 29. South America Drug-Resistant Tuberculosis Treatment, by Disease Type USD Million (2015-2020)
  • Table 30. South America Drug-Resistant Tuberculosis Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 31. South America Drug-Resistant Tuberculosis Treatment, by Treatment Type USD Million (2015-2020)
  • Table 32. Brazil Drug-Resistant Tuberculosis Treatment, by Type USD Million (2015-2020)
  • Table 33. Brazil Drug-Resistant Tuberculosis Treatment, by Application USD Million (2015-2020)
  • Table 34. Brazil Drug-Resistant Tuberculosis Treatment, by Disease Type USD Million (2015-2020)
  • Table 35. Brazil Drug-Resistant Tuberculosis Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 36. Brazil Drug-Resistant Tuberculosis Treatment, by Treatment Type USD Million (2015-2020)
  • Table 37. Argentina Drug-Resistant Tuberculosis Treatment, by Type USD Million (2015-2020)
  • Table 38. Argentina Drug-Resistant Tuberculosis Treatment, by Application USD Million (2015-2020)
  • Table 39. Argentina Drug-Resistant Tuberculosis Treatment, by Disease Type USD Million (2015-2020)
  • Table 40. Argentina Drug-Resistant Tuberculosis Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 41. Argentina Drug-Resistant Tuberculosis Treatment, by Treatment Type USD Million (2015-2020)
  • Table 42. Rest of South America Drug-Resistant Tuberculosis Treatment, by Type USD Million (2015-2020)
  • Table 43. Rest of South America Drug-Resistant Tuberculosis Treatment, by Application USD Million (2015-2020)
  • Table 44. Rest of South America Drug-Resistant Tuberculosis Treatment, by Disease Type USD Million (2015-2020)
  • Table 45. Rest of South America Drug-Resistant Tuberculosis Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 46. Rest of South America Drug-Resistant Tuberculosis Treatment, by Treatment Type USD Million (2015-2020)
  • Table 47. Asia Pacific Drug-Resistant Tuberculosis Treatment, by Country USD Million (2015-2020)
  • Table 48. Asia Pacific Drug-Resistant Tuberculosis Treatment, by Type USD Million (2015-2020)
  • Table 49. Asia Pacific Drug-Resistant Tuberculosis Treatment, by Application USD Million (2015-2020)
  • Table 50. Asia Pacific Drug-Resistant Tuberculosis Treatment, by Disease Type USD Million (2015-2020)
  • Table 51. Asia Pacific Drug-Resistant Tuberculosis Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 52. Asia Pacific Drug-Resistant Tuberculosis Treatment, by Treatment Type USD Million (2015-2020)
  • Table 53. China Drug-Resistant Tuberculosis Treatment, by Type USD Million (2015-2020)
  • Table 54. China Drug-Resistant Tuberculosis Treatment, by Application USD Million (2015-2020)
  • Table 55. China Drug-Resistant Tuberculosis Treatment, by Disease Type USD Million (2015-2020)
  • Table 56. China Drug-Resistant Tuberculosis Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 57. China Drug-Resistant Tuberculosis Treatment, by Treatment Type USD Million (2015-2020)
  • Table 58. Japan Drug-Resistant Tuberculosis Treatment, by Type USD Million (2015-2020)
  • Table 59. Japan Drug-Resistant Tuberculosis Treatment, by Application USD Million (2015-2020)
  • Table 60. Japan Drug-Resistant Tuberculosis Treatment, by Disease Type USD Million (2015-2020)
  • Table 61. Japan Drug-Resistant Tuberculosis Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 62. Japan Drug-Resistant Tuberculosis Treatment, by Treatment Type USD Million (2015-2020)
  • Table 63. India Drug-Resistant Tuberculosis Treatment, by Type USD Million (2015-2020)
  • Table 64. India Drug-Resistant Tuberculosis Treatment, by Application USD Million (2015-2020)
  • Table 65. India Drug-Resistant Tuberculosis Treatment, by Disease Type USD Million (2015-2020)
  • Table 66. India Drug-Resistant Tuberculosis Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 67. India Drug-Resistant Tuberculosis Treatment, by Treatment Type USD Million (2015-2020)
  • Table 68. South Korea Drug-Resistant Tuberculosis Treatment, by Type USD Million (2015-2020)
  • Table 69. South Korea Drug-Resistant Tuberculosis Treatment, by Application USD Million (2015-2020)
  • Table 70. South Korea Drug-Resistant Tuberculosis Treatment, by Disease Type USD Million (2015-2020)
  • Table 71. South Korea Drug-Resistant Tuberculosis Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 72. South Korea Drug-Resistant Tuberculosis Treatment, by Treatment Type USD Million (2015-2020)
  • Table 73. Taiwan Drug-Resistant Tuberculosis Treatment, by Type USD Million (2015-2020)
  • Table 74. Taiwan Drug-Resistant Tuberculosis Treatment, by Application USD Million (2015-2020)
  • Table 75. Taiwan Drug-Resistant Tuberculosis Treatment, by Disease Type USD Million (2015-2020)
  • Table 76. Taiwan Drug-Resistant Tuberculosis Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 77. Taiwan Drug-Resistant Tuberculosis Treatment, by Treatment Type USD Million (2015-2020)
  • Table 78. Australia Drug-Resistant Tuberculosis Treatment, by Type USD Million (2015-2020)
  • Table 79. Australia Drug-Resistant Tuberculosis Treatment, by Application USD Million (2015-2020)
  • Table 80. Australia Drug-Resistant Tuberculosis Treatment, by Disease Type USD Million (2015-2020)
  • Table 81. Australia Drug-Resistant Tuberculosis Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 82. Australia Drug-Resistant Tuberculosis Treatment, by Treatment Type USD Million (2015-2020)
  • Table 83. Rest of Asia-Pacific Drug-Resistant Tuberculosis Treatment, by Type USD Million (2015-2020)
  • Table 84. Rest of Asia-Pacific Drug-Resistant Tuberculosis Treatment, by Application USD Million (2015-2020)
  • Table 85. Rest of Asia-Pacific Drug-Resistant Tuberculosis Treatment, by Disease Type USD Million (2015-2020)
  • Table 86. Rest of Asia-Pacific Drug-Resistant Tuberculosis Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 87. Rest of Asia-Pacific Drug-Resistant Tuberculosis Treatment, by Treatment Type USD Million (2015-2020)
  • Table 88. Europe Drug-Resistant Tuberculosis Treatment, by Country USD Million (2015-2020)
  • Table 89. Europe Drug-Resistant Tuberculosis Treatment, by Type USD Million (2015-2020)
  • Table 90. Europe Drug-Resistant Tuberculosis Treatment, by Application USD Million (2015-2020)
  • Table 91. Europe Drug-Resistant Tuberculosis Treatment, by Disease Type USD Million (2015-2020)
  • Table 92. Europe Drug-Resistant Tuberculosis Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 93. Europe Drug-Resistant Tuberculosis Treatment, by Treatment Type USD Million (2015-2020)
  • Table 94. Germany Drug-Resistant Tuberculosis Treatment, by Type USD Million (2015-2020)
  • Table 95. Germany Drug-Resistant Tuberculosis Treatment, by Application USD Million (2015-2020)
  • Table 96. Germany Drug-Resistant Tuberculosis Treatment, by Disease Type USD Million (2015-2020)
  • Table 97. Germany Drug-Resistant Tuberculosis Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 98. Germany Drug-Resistant Tuberculosis Treatment, by Treatment Type USD Million (2015-2020)
  • Table 99. France Drug-Resistant Tuberculosis Treatment, by Type USD Million (2015-2020)
  • Table 100. France Drug-Resistant Tuberculosis Treatment, by Application USD Million (2015-2020)
  • Table 101. France Drug-Resistant Tuberculosis Treatment, by Disease Type USD Million (2015-2020)
  • Table 102. France Drug-Resistant Tuberculosis Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 103. France Drug-Resistant Tuberculosis Treatment, by Treatment Type USD Million (2015-2020)
  • Table 104. Italy Drug-Resistant Tuberculosis Treatment, by Type USD Million (2015-2020)
  • Table 105. Italy Drug-Resistant Tuberculosis Treatment, by Application USD Million (2015-2020)
  • Table 106. Italy Drug-Resistant Tuberculosis Treatment, by Disease Type USD Million (2015-2020)
  • Table 107. Italy Drug-Resistant Tuberculosis Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 108. Italy Drug-Resistant Tuberculosis Treatment, by Treatment Type USD Million (2015-2020)
  • Table 109. United Kingdom Drug-Resistant Tuberculosis Treatment, by Type USD Million (2015-2020)
  • Table 110. United Kingdom Drug-Resistant Tuberculosis Treatment, by Application USD Million (2015-2020)
  • Table 111. United Kingdom Drug-Resistant Tuberculosis Treatment, by Disease Type USD Million (2015-2020)
  • Table 112. United Kingdom Drug-Resistant Tuberculosis Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 113. United Kingdom Drug-Resistant Tuberculosis Treatment, by Treatment Type USD Million (2015-2020)
  • Table 114. Netherlands Drug-Resistant Tuberculosis Treatment, by Type USD Million (2015-2020)
  • Table 115. Netherlands Drug-Resistant Tuberculosis Treatment, by Application USD Million (2015-2020)
  • Table 116. Netherlands Drug-Resistant Tuberculosis Treatment, by Disease Type USD Million (2015-2020)
  • Table 117. Netherlands Drug-Resistant Tuberculosis Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 118. Netherlands Drug-Resistant Tuberculosis Treatment, by Treatment Type USD Million (2015-2020)
  • Table 119. Rest of Europe Drug-Resistant Tuberculosis Treatment, by Type USD Million (2015-2020)
  • Table 120. Rest of Europe Drug-Resistant Tuberculosis Treatment, by Application USD Million (2015-2020)
  • Table 121. Rest of Europe Drug-Resistant Tuberculosis Treatment, by Disease Type USD Million (2015-2020)
  • Table 122. Rest of Europe Drug-Resistant Tuberculosis Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 123. Rest of Europe Drug-Resistant Tuberculosis Treatment, by Treatment Type USD Million (2015-2020)
  • Table 124. MEA Drug-Resistant Tuberculosis Treatment, by Country USD Million (2015-2020)
  • Table 125. MEA Drug-Resistant Tuberculosis Treatment, by Type USD Million (2015-2020)
  • Table 126. MEA Drug-Resistant Tuberculosis Treatment, by Application USD Million (2015-2020)
  • Table 127. MEA Drug-Resistant Tuberculosis Treatment, by Disease Type USD Million (2015-2020)
  • Table 128. MEA Drug-Resistant Tuberculosis Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 129. MEA Drug-Resistant Tuberculosis Treatment, by Treatment Type USD Million (2015-2020)
  • Table 130. Middle East Drug-Resistant Tuberculosis Treatment, by Type USD Million (2015-2020)
  • Table 131. Middle East Drug-Resistant Tuberculosis Treatment, by Application USD Million (2015-2020)
  • Table 132. Middle East Drug-Resistant Tuberculosis Treatment, by Disease Type USD Million (2015-2020)
  • Table 133. Middle East Drug-Resistant Tuberculosis Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 134. Middle East Drug-Resistant Tuberculosis Treatment, by Treatment Type USD Million (2015-2020)
  • Table 135. Africa Drug-Resistant Tuberculosis Treatment, by Type USD Million (2015-2020)
  • Table 136. Africa Drug-Resistant Tuberculosis Treatment, by Application USD Million (2015-2020)
  • Table 137. Africa Drug-Resistant Tuberculosis Treatment, by Disease Type USD Million (2015-2020)
  • Table 138. Africa Drug-Resistant Tuberculosis Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 139. Africa Drug-Resistant Tuberculosis Treatment, by Treatment Type USD Million (2015-2020)
  • Table 140. North America Drug-Resistant Tuberculosis Treatment, by Country USD Million (2015-2020)
  • Table 141. North America Drug-Resistant Tuberculosis Treatment, by Type USD Million (2015-2020)
  • Table 142. North America Drug-Resistant Tuberculosis Treatment, by Application USD Million (2015-2020)
  • Table 143. North America Drug-Resistant Tuberculosis Treatment, by Disease Type USD Million (2015-2020)
  • Table 144. North America Drug-Resistant Tuberculosis Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 145. North America Drug-Resistant Tuberculosis Treatment, by Treatment Type USD Million (2015-2020)
  • Table 146. United States Drug-Resistant Tuberculosis Treatment, by Type USD Million (2015-2020)
  • Table 147. United States Drug-Resistant Tuberculosis Treatment, by Application USD Million (2015-2020)
  • Table 148. United States Drug-Resistant Tuberculosis Treatment, by Disease Type USD Million (2015-2020)
  • Table 149. United States Drug-Resistant Tuberculosis Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 150. United States Drug-Resistant Tuberculosis Treatment, by Treatment Type USD Million (2015-2020)
  • Table 151. Canada Drug-Resistant Tuberculosis Treatment, by Type USD Million (2015-2020)
  • Table 152. Canada Drug-Resistant Tuberculosis Treatment, by Application USD Million (2015-2020)
  • Table 153. Canada Drug-Resistant Tuberculosis Treatment, by Disease Type USD Million (2015-2020)
  • Table 154. Canada Drug-Resistant Tuberculosis Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 155. Canada Drug-Resistant Tuberculosis Treatment, by Treatment Type USD Million (2015-2020)
  • Table 156. Mexico Drug-Resistant Tuberculosis Treatment, by Type USD Million (2015-2020)
  • Table 157. Mexico Drug-Resistant Tuberculosis Treatment, by Application USD Million (2015-2020)
  • Table 158. Mexico Drug-Resistant Tuberculosis Treatment, by Disease Type USD Million (2015-2020)
  • Table 159. Mexico Drug-Resistant Tuberculosis Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 160. Mexico Drug-Resistant Tuberculosis Treatment, by Treatment Type USD Million (2015-2020)
  • Table 161. Drug-Resistant Tuberculosis Treatment Sales: by Type(K Units)
  • Table 162. Drug-Resistant Tuberculosis Treatment Sales Amoxicillin/Clavulanate , by Region K Units (2015-2020)
  • Table 163. Drug-Resistant Tuberculosis Treatment Sales Bedaquiline , by Region K Units (2015-2020)
  • Table 164. Drug-Resistant Tuberculosis Treatment Sales Carbapenems with Clavulanic Acid , by Region K Units (2015-2020)
  • Table 165. Drug-Resistant Tuberculosis Treatment Sales Clofazimine , by Region K Units (2015-2020)
  • Table 166. Drug-Resistant Tuberculosis Treatment Sales Cycloserine , by Region K Units (2015-2020)
  • Table 167. Drug-Resistant Tuberculosis Treatment Sales Delamanid , by Region K Units (2015-2020)
  • Table 168. Drug-Resistant Tuberculosis Treatment Sales Ethambutol , by Region K Units (2015-2020)
  • Table 169. Drug-Resistant Tuberculosis Treatment Sales Others , by Region K Units (2015-2020)
  • Table 170. Drug-Resistant Tuberculosis Treatment Sales: by Application(K Units)
  • Table 171. Drug-Resistant Tuberculosis Treatment Sales Hospital , by Region K Units (2015-2020)
  • Table 172. Drug-Resistant Tuberculosis Treatment Sales Clinics , by Region K Units (2015-2020)
  • Table 173. Drug-Resistant Tuberculosis Treatment Sales Others , by Region K Units (2015-2020)
  • Table 174. Drug-Resistant Tuberculosis Treatment Sales: by Disease Type(K Units)
  • Table 175. Drug-Resistant Tuberculosis Treatment Sales Multidrug-Resistant TB (MDR TB) , by Region K Units (2015-2020)
  • Table 176. Drug-Resistant Tuberculosis Treatment Sales Extensively Drug-resistant TB (XDR TB) , by Region K Units (2015-2020)
  • Table 177. Drug-Resistant Tuberculosis Treatment Sales: by Distribution Channel(K Units)
  • Table 178. Drug-Resistant Tuberculosis Treatment Sales Hospital Pharmacy , by Region K Units (2015-2020)
  • Table 179. Drug-Resistant Tuberculosis Treatment Sales Online Pharmacy , by Region K Units (2015-2020)
  • Table 180. Drug-Resistant Tuberculosis Treatment Sales Retail Pharmacy , by Region K Units (2015-2020)
  • Table 181. Drug-Resistant Tuberculosis Treatment Sales Others , by Region K Units (2015-2020)
  • Table 182. Drug-Resistant Tuberculosis Treatment Sales: by Treatment Type(K Units)
  • Table 183. Drug-Resistant Tuberculosis Treatment Sales First-Line Anti-TB Drugs , by Region K Units (2015-2020)
  • Table 184. Drug-Resistant Tuberculosis Treatment Sales Second-Line Anti-TB Drugs , by Region K Units (2015-2020)
  • Table 185. Drug-Resistant Tuberculosis Treatment Sales Others , by Region K Units (2015-2020)
  • Table 186. South America Drug-Resistant Tuberculosis Treatment Sales, by Country K Units (2015-2020)
  • Table 187. South America Drug-Resistant Tuberculosis Treatment Sales, by Type K Units (2015-2020)
  • Table 188. South America Drug-Resistant Tuberculosis Treatment Sales, by Application K Units (2015-2020)
  • Table 189. South America Drug-Resistant Tuberculosis Treatment Sales, by Disease Type K Units (2015-2020)
  • Table 190. South America Drug-Resistant Tuberculosis Treatment Sales, by Distribution Channel K Units (2015-2020)
  • Table 191. South America Drug-Resistant Tuberculosis Treatment Sales, by Treatment Type K Units (2015-2020)
  • Table 192. Brazil Drug-Resistant Tuberculosis Treatment Sales, by Type K Units (2015-2020)
  • Table 193. Brazil Drug-Resistant Tuberculosis Treatment Sales, by Application K Units (2015-2020)
  • Table 194. Brazil Drug-Resistant Tuberculosis Treatment Sales, by Disease Type K Units (2015-2020)
  • Table 195. Brazil Drug-Resistant Tuberculosis Treatment Sales, by Distribution Channel K Units (2015-2020)
  • Table 196. Brazil Drug-Resistant Tuberculosis Treatment Sales, by Treatment Type K Units (2015-2020)
  • Table 197. Argentina Drug-Resistant Tuberculosis Treatment Sales, by Type K Units (2015-2020)
  • Table 198. Argentina Drug-Resistant Tuberculosis Treatment Sales, by Application K Units (2015-2020)
  • Table 199. Argentina Drug-Resistant Tuberculosis Treatment Sales, by Disease Type K Units (2015-2020)
  • Table 200. Argentina Drug-Resistant Tuberculosis Treatment Sales, by Distribution Channel K Units (2015-2020)
  • Table 201. Argentina Drug-Resistant Tuberculosis Treatment Sales, by Treatment Type K Units (2015-2020)
  • Table 202. Rest of South America Drug-Resistant Tuberculosis Treatment Sales, by Type K Units (2015-2020)
  • Table 203. Rest of South America Drug-Resistant Tuberculosis Treatment Sales, by Application K Units (2015-2020)
  • Table 204. Rest of South America Drug-Resistant Tuberculosis Treatment Sales, by Disease Type K Units (2015-2020)
  • Table 205. Rest of South America Drug-Resistant Tuberculosis Treatment Sales, by Distribution Channel K Units (2015-2020)
  • Table 206. Rest of South America Drug-Resistant Tuberculosis Treatment Sales, by Treatment Type K Units (2015-2020)
  • Table 207. Asia Pacific Drug-Resistant Tuberculosis Treatment Sales, by Country K Units (2015-2020)
  • Table 208. Asia Pacific Drug-Resistant Tuberculosis Treatment Sales, by Type K Units (2015-2020)
  • Table 209. Asia Pacific Drug-Resistant Tuberculosis Treatment Sales, by Application K Units (2015-2020)
  • Table 210. Asia Pacific Drug-Resistant Tuberculosis Treatment Sales, by Disease Type K Units (2015-2020)
  • Table 211. Asia Pacific Drug-Resistant Tuberculosis Treatment Sales, by Distribution Channel K Units (2015-2020)
  • Table 212. Asia Pacific Drug-Resistant Tuberculosis Treatment Sales, by Treatment Type K Units (2015-2020)
  • Table 213. China Drug-Resistant Tuberculosis Treatment Sales, by Type K Units (2015-2020)
  • Table 214. China Drug-Resistant Tuberculosis Treatment Sales, by Application K Units (2015-2020)
  • Table 215. China Drug-Resistant Tuberculosis Treatment Sales, by Disease Type K Units (2015-2020)
  • Table 216. China Drug-Resistant Tuberculosis Treatment Sales, by Distribution Channel K Units (2015-2020)
  • Table 217. China Drug-Resistant Tuberculosis Treatment Sales, by Treatment Type K Units (2015-2020)
  • Table 218. Japan Drug-Resistant Tuberculosis Treatment Sales, by Type K Units (2015-2020)
  • Table 219. Japan Drug-Resistant Tuberculosis Treatment Sales, by Application K Units (2015-2020)
  • Table 220. Japan Drug-Resistant Tuberculosis Treatment Sales, by Disease Type K Units (2015-2020)
  • Table 221. Japan Drug-Resistant Tuberculosis Treatment Sales, by Distribution Channel K Units (2015-2020)
  • Table 222. Japan Drug-Resistant Tuberculosis Treatment Sales, by Treatment Type K Units (2015-2020)
  • Table 223. India Drug-Resistant Tuberculosis Treatment Sales, by Type K Units (2015-2020)
  • Table 224. India Drug-Resistant Tuberculosis Treatment Sales, by Application K Units (2015-2020)
  • Table 225. India Drug-Resistant Tuberculosis Treatment Sales, by Disease Type K Units (2015-2020)
  • Table 226. India Drug-Resistant Tuberculosis Treatment Sales, by Distribution Channel K Units (2015-2020)
  • Table 227. India Drug-Resistant Tuberculosis Treatment Sales, by Treatment Type K Units (2015-2020)
  • Table 228. South Korea Drug-Resistant Tuberculosis Treatment Sales, by Type K Units (2015-2020)
  • Table 229. South Korea Drug-Resistant Tuberculosis Treatment Sales, by Application K Units (2015-2020)
  • Table 230. South Korea Drug-Resistant Tuberculosis Treatment Sales, by Disease Type K Units (2015-2020)
  • Table 231. South Korea Drug-Resistant Tuberculosis Treatment Sales, by Distribution Channel K Units (2015-2020)
  • Table 232. South Korea Drug-Resistant Tuberculosis Treatment Sales, by Treatment Type K Units (2015-2020)
  • Table 233. Taiwan Drug-Resistant Tuberculosis Treatment Sales, by Type K Units (2015-2020)
  • Table 234. Taiwan Drug-Resistant Tuberculosis Treatment Sales, by Application K Units (2015-2020)
  • Table 235. Taiwan Drug-Resistant Tuberculosis Treatment Sales, by Disease Type K Units (2015-2020)
  • Table 236. Taiwan Drug-Resistant Tuberculosis Treatment Sales, by Distribution Channel K Units (2015-2020)
  • Table 237. Taiwan Drug-Resistant Tuberculosis Treatment Sales, by Treatment Type K Units (2015-2020)
  • Table 238. Australia Drug-Resistant Tuberculosis Treatment Sales, by Type K Units (2015-2020)
  • Table 239. Australia Drug-Resistant Tuberculosis Treatment Sales, by Application K Units (2015-2020)
  • Table 240. Australia Drug-Resistant Tuberculosis Treatment Sales, by Disease Type K Units (2015-2020)
  • Table 241. Australia Drug-Resistant Tuberculosis Treatment Sales, by Distribution Channel K Units (2015-2020)
  • Table 242. Australia Drug-Resistant Tuberculosis Treatment Sales, by Treatment Type K Units (2015-2020)
  • Table 243. Rest of Asia-Pacific Drug-Resistant Tuberculosis Treatment Sales, by Type K Units (2015-2020)
  • Table 244. Rest of Asia-Pacific Drug-Resistant Tuberculosis Treatment Sales, by Application K Units (2015-2020)
  • Table 245. Rest of Asia-Pacific Drug-Resistant Tuberculosis Treatment Sales, by Disease Type K Units (2015-2020)
  • Table 246. Rest of Asia-Pacific Drug-Resistant Tuberculosis Treatment Sales, by Distribution Channel K Units (2015-2020)
  • Table 247. Rest of Asia-Pacific Drug-Resistant Tuberculosis Treatment Sales, by Treatment Type K Units (2015-2020)
  • Table 248. Europe Drug-Resistant Tuberculosis Treatment Sales, by Country K Units (2015-2020)
  • Table 249. Europe Drug-Resistant Tuberculosis Treatment Sales, by Type K Units (2015-2020)
  • Table 250. Europe Drug-Resistant Tuberculosis Treatment Sales, by Application K Units (2015-2020)
  • Table 251. Europe Drug-Resistant Tuberculosis Treatment Sales, by Disease Type K Units (2015-2020)
  • Table 252. Europe Drug-Resistant Tuberculosis Treatment Sales, by Distribution Channel K Units (2015-2020)
  • Table 253. Europe Drug-Resistant Tuberculosis Treatment Sales, by Treatment Type K Units (2015-2020)
  • Table 254. Germany Drug-Resistant Tuberculosis Treatment Sales, by Type K Units (2015-2020)
  • Table 255. Germany Drug-Resistant Tuberculosis Treatment Sales, by Application K Units (2015-2020)
  • Table 256. Germany Drug-Resistant Tuberculosis Treatment Sales, by Disease Type K Units (2015-2020)
  • Table 257. Germany Drug-Resistant Tuberculosis Treatment Sales, by Distribution Channel K Units (2015-2020)
  • Table 258. Germany Drug-Resistant Tuberculosis Treatment Sales, by Treatment Type K Units (2015-2020)
  • Table 259. France Drug-Resistant Tuberculosis Treatment Sales, by Type K Units (2015-2020)
  • Table 260. France Drug-Resistant Tuberculosis Treatment Sales, by Application K Units (2015-2020)
  • Table 261. France Drug-Resistant Tuberculosis Treatment Sales, by Disease Type K Units (2015-2020)
  • Table 262. France Drug-Resistant Tuberculosis Treatment Sales, by Distribution Channel K Units (2015-2020)
  • Table 263. France Drug-Resistant Tuberculosis Treatment Sales, by Treatment Type K Units (2015-2020)
  • Table 264. Italy Drug-Resistant Tuberculosis Treatment Sales, by Type K Units (2015-2020)
  • Table 265. Italy Drug-Resistant Tuberculosis Treatment Sales, by Application K Units (2015-2020)
  • Table 266. Italy Drug-Resistant Tuberculosis Treatment Sales, by Disease Type K Units (2015-2020)
  • Table 267. Italy Drug-Resistant Tuberculosis Treatment Sales, by Distribution Channel K Units (2015-2020)
  • Table 268. Italy Drug-Resistant Tuberculosis Treatment Sales, by Treatment Type K Units (2015-2020)
  • Table 269. United Kingdom Drug-Resistant Tuberculosis Treatment Sales, by Type K Units (2015-2020)
  • Table 270. United Kingdom Drug-Resistant Tuberculosis Treatment Sales, by Application K Units (2015-2020)
  • Table 271. United Kingdom Drug-Resistant Tuberculosis Treatment Sales, by Disease Type K Units (2015-2020)
  • Table 272. United Kingdom Drug-Resistant Tuberculosis Treatment Sales, by Distribution Channel K Units (2015-2020)
  • Table 273. United Kingdom Drug-Resistant Tuberculosis Treatment Sales, by Treatment Type K Units (2015-2020)
  • Table 274. Netherlands Drug-Resistant Tuberculosis Treatment Sales, by Type K Units (2015-2020)
  • Table 275. Netherlands Drug-Resistant Tuberculosis Treatment Sales, by Application K Units (2015-2020)
  • Table 276. Netherlands Drug-Resistant Tuberculosis Treatment Sales, by Disease Type K Units (2015-2020)
  • Table 277. Netherlands Drug-Resistant Tuberculosis Treatment Sales, by Distribution Channel K Units (2015-2020)
  • Table 278. Netherlands Drug-Resistant Tuberculosis Treatment Sales, by Treatment Type K Units (2015-2020)
  • Table 279. Rest of Europe Drug-Resistant Tuberculosis Treatment Sales, by Type K Units (2015-2020)
  • Table 280. Rest of Europe Drug-Resistant Tuberculosis Treatment Sales, by Application K Units (2015-2020)
  • Table 281. Rest of Europe Drug-Resistant Tuberculosis Treatment Sales, by Disease Type K Units (2015-2020)
  • Table 282. Rest of Europe Drug-Resistant Tuberculosis Treatment Sales, by Distribution Channel K Units (2015-2020)
  • Table 283. Rest of Europe Drug-Resistant Tuberculosis Treatment Sales, by Treatment Type K Units (2015-2020)
  • Table 284. MEA Drug-Resistant Tuberculosis Treatment Sales, by Country K Units (2015-2020)
  • Table 285. MEA Drug-Resistant Tuberculosis Treatment Sales, by Type K Units (2015-2020)
  • Table 286. MEA Drug-Resistant Tuberculosis Treatment Sales, by Application K Units (2015-2020)
  • Table 287. MEA Drug-Resistant Tuberculosis Treatment Sales, by Disease Type K Units (2015-2020)
  • Table 288. MEA Drug-Resistant Tuberculosis Treatment Sales, by Distribution Channel K Units (2015-2020)
  • Table 289. MEA Drug-Resistant Tuberculosis Treatment Sales, by Treatment Type K Units (2015-2020)
  • Table 290. Middle East Drug-Resistant Tuberculosis Treatment Sales, by Type K Units (2015-2020)
  • Table 291. Middle East Drug-Resistant Tuberculosis Treatment Sales, by Application K Units (2015-2020)
  • Table 292. Middle East Drug-Resistant Tuberculosis Treatment Sales, by Disease Type K Units (2015-2020)
  • Table 293. Middle East Drug-Resistant Tuberculosis Treatment Sales, by Distribution Channel K Units (2015-2020)
  • Table 294. Middle East Drug-Resistant Tuberculosis Treatment Sales, by Treatment Type K Units (2015-2020)
  • Table 295. Africa Drug-Resistant Tuberculosis Treatment Sales, by Type K Units (2015-2020)
  • Table 296. Africa Drug-Resistant Tuberculosis Treatment Sales, by Application K Units (2015-2020)
  • Table 297. Africa Drug-Resistant Tuberculosis Treatment Sales, by Disease Type K Units (2015-2020)
  • Table 298. Africa Drug-Resistant Tuberculosis Treatment Sales, by Distribution Channel K Units (2015-2020)
  • Table 299. Africa Drug-Resistant Tuberculosis Treatment Sales, by Treatment Type K Units (2015-2020)
  • Table 300. North America Drug-Resistant Tuberculosis Treatment Sales, by Country K Units (2015-2020)
  • Table 301. North America Drug-Resistant Tuberculosis Treatment Sales, by Type K Units (2015-2020)
  • Table 302. North America Drug-Resistant Tuberculosis Treatment Sales, by Application K Units (2015-2020)
  • Table 303. North America Drug-Resistant Tuberculosis Treatment Sales, by Disease Type K Units (2015-2020)
  • Table 304. North America Drug-Resistant Tuberculosis Treatment Sales, by Distribution Channel K Units (2015-2020)
  • Table 305. North America Drug-Resistant Tuberculosis Treatment Sales, by Treatment Type K Units (2015-2020)
  • Table 306. United States Drug-Resistant Tuberculosis Treatment Sales, by Type K Units (2015-2020)
  • Table 307. United States Drug-Resistant Tuberculosis Treatment Sales, by Application K Units (2015-2020)
  • Table 308. United States Drug-Resistant Tuberculosis Treatment Sales, by Disease Type K Units (2015-2020)
  • Table 309. United States Drug-Resistant Tuberculosis Treatment Sales, by Distribution Channel K Units (2015-2020)
  • Table 310. United States Drug-Resistant Tuberculosis Treatment Sales, by Treatment Type K Units (2015-2020)
  • Table 311. Canada Drug-Resistant Tuberculosis Treatment Sales, by Type K Units (2015-2020)
  • Table 312. Canada Drug-Resistant Tuberculosis Treatment Sales, by Application K Units (2015-2020)
  • Table 313. Canada Drug-Resistant Tuberculosis Treatment Sales, by Disease Type K Units (2015-2020)
  • Table 314. Canada Drug-Resistant Tuberculosis Treatment Sales, by Distribution Channel K Units (2015-2020)
  • Table 315. Canada Drug-Resistant Tuberculosis Treatment Sales, by Treatment Type K Units (2015-2020)
  • Table 316. Mexico Drug-Resistant Tuberculosis Treatment Sales, by Type K Units (2015-2020)
  • Table 317. Mexico Drug-Resistant Tuberculosis Treatment Sales, by Application K Units (2015-2020)
  • Table 318. Mexico Drug-Resistant Tuberculosis Treatment Sales, by Disease Type K Units (2015-2020)
  • Table 319. Mexico Drug-Resistant Tuberculosis Treatment Sales, by Distribution Channel K Units (2015-2020)
  • Table 320. Mexico Drug-Resistant Tuberculosis Treatment Sales, by Treatment Type K Units (2015-2020)
  • Table 321. Drug-Resistant Tuberculosis Treatment: by Type(USD/Units)
  • Table 322. Company Basic Information, Sales Area and Its Competitors
  • Table 323. Company Basic Information, Sales Area and Its Competitors
  • Table 324. Company Basic Information, Sales Area and Its Competitors
  • Table 325. Company Basic Information, Sales Area and Its Competitors
  • Table 326. Company Basic Information, Sales Area and Its Competitors
  • Table 327. Company Basic Information, Sales Area and Its Competitors
  • Table 328. Company Basic Information, Sales Area and Its Competitors
  • Table 329. Company Basic Information, Sales Area and Its Competitors
  • Table 330. Company Basic Information, Sales Area and Its Competitors
  • Table 331. Company Basic Information, Sales Area and Its Competitors
  • Table 332. Company Basic Information, Sales Area and Its Competitors
  • Table 333. Company Basic Information, Sales Area and Its Competitors
  • Table 334. Drug-Resistant Tuberculosis Treatment: by Type(USD Million)
  • Table 335. Drug-Resistant Tuberculosis Treatment Amoxicillin/Clavulanate , by Region USD Million (2021-2026)
  • Table 336. Drug-Resistant Tuberculosis Treatment Bedaquiline , by Region USD Million (2021-2026)
  • Table 337. Drug-Resistant Tuberculosis Treatment Carbapenems with Clavulanic Acid , by Region USD Million (2021-2026)
  • Table 338. Drug-Resistant Tuberculosis Treatment Clofazimine , by Region USD Million (2021-2026)
  • Table 339. Drug-Resistant Tuberculosis Treatment Cycloserine , by Region USD Million (2021-2026)
  • Table 340. Drug-Resistant Tuberculosis Treatment Delamanid , by Region USD Million (2021-2026)
  • Table 341. Drug-Resistant Tuberculosis Treatment Ethambutol , by Region USD Million (2021-2026)
  • Table 342. Drug-Resistant Tuberculosis Treatment Others , by Region USD Million (2021-2026)
  • Table 343. Drug-Resistant Tuberculosis Treatment: by Application(USD Million)
  • Table 344. Drug-Resistant Tuberculosis Treatment Hospital , by Region USD Million (2021-2026)
  • Table 345. Drug-Resistant Tuberculosis Treatment Clinics , by Region USD Million (2021-2026)
  • Table 346. Drug-Resistant Tuberculosis Treatment Others , by Region USD Million (2021-2026)
  • Table 347. Drug-Resistant Tuberculosis Treatment: by Disease Type(USD Million)
  • Table 348. Drug-Resistant Tuberculosis Treatment Multidrug-Resistant TB (MDR TB) , by Region USD Million (2021-2026)
  • Table 349. Drug-Resistant Tuberculosis Treatment Extensively Drug-resistant TB (XDR TB) , by Region USD Million (2021-2026)
  • Table 350. Drug-Resistant Tuberculosis Treatment: by Distribution Channel(USD Million)
  • Table 351. Drug-Resistant Tuberculosis Treatment Hospital Pharmacy , by Region USD Million (2021-2026)
  • Table 352. Drug-Resistant Tuberculosis Treatment Online Pharmacy , by Region USD Million (2021-2026)
  • Table 353. Drug-Resistant Tuberculosis Treatment Retail Pharmacy , by Region USD Million (2021-2026)
  • Table 354. Drug-Resistant Tuberculosis Treatment Others , by Region USD Million (2021-2026)
  • Table 355. Drug-Resistant Tuberculosis Treatment: by Treatment Type(USD Million)
  • Table 356. Drug-Resistant Tuberculosis Treatment First-Line Anti-TB Drugs , by Region USD Million (2021-2026)
  • Table 357. Drug-Resistant Tuberculosis Treatment Second-Line Anti-TB Drugs , by Region USD Million (2021-2026)
  • Table 358. Drug-Resistant Tuberculosis Treatment Others , by Region USD Million (2021-2026)
  • Table 359. South America Drug-Resistant Tuberculosis Treatment, by Country USD Million (2021-2026)
  • Table 360. South America Drug-Resistant Tuberculosis Treatment, by Type USD Million (2021-2026)
  • Table 361. South America Drug-Resistant Tuberculosis Treatment, by Application USD Million (2021-2026)
  • Table 362. South America Drug-Resistant Tuberculosis Treatment, by Disease Type USD Million (2021-2026)
  • Table 363. South America Drug-Resistant Tuberculosis Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 364. South America Drug-Resistant Tuberculosis Treatment, by Treatment Type USD Million (2021-2026)
  • Table 365. Brazil Drug-Resistant Tuberculosis Treatment, by Type USD Million (2021-2026)
  • Table 366. Brazil Drug-Resistant Tuberculosis Treatment, by Application USD Million (2021-2026)
  • Table 367. Brazil Drug-Resistant Tuberculosis Treatment, by Disease Type USD Million (2021-2026)
  • Table 368. Brazil Drug-Resistant Tuberculosis Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 369. Brazil Drug-Resistant Tuberculosis Treatment, by Treatment Type USD Million (2021-2026)
  • Table 370. Argentina Drug-Resistant Tuberculosis Treatment, by Type USD Million (2021-2026)
  • Table 371. Argentina Drug-Resistant Tuberculosis Treatment, by Application USD Million (2021-2026)
  • Table 372. Argentina Drug-Resistant Tuberculosis Treatment, by Disease Type USD Million (2021-2026)
  • Table 373. Argentina Drug-Resistant Tuberculosis Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 374. Argentina Drug-Resistant Tuberculosis Treatment, by Treatment Type USD Million (2021-2026)
  • Table 375. Rest of South America Drug-Resistant Tuberculosis Treatment, by Type USD Million (2021-2026)
  • Table 376. Rest of South America Drug-Resistant Tuberculosis Treatment, by Application USD Million (2021-2026)
  • Table 377. Rest of South America Drug-Resistant Tuberculosis Treatment, by Disease Type USD Million (2021-2026)
  • Table 378. Rest of South America Drug-Resistant Tuberculosis Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 379. Rest of South America Drug-Resistant Tuberculosis Treatment, by Treatment Type USD Million (2021-2026)
  • Table 380. Asia Pacific Drug-Resistant Tuberculosis Treatment, by Country USD Million (2021-2026)
  • Table 381. Asia Pacific Drug-Resistant Tuberculosis Treatment, by Type USD Million (2021-2026)
  • Table 382. Asia Pacific Drug-Resistant Tuberculosis Treatment, by Application USD Million (2021-2026)
  • Table 383. Asia Pacific Drug-Resistant Tuberculosis Treatment, by Disease Type USD Million (2021-2026)
  • Table 384. Asia Pacific Drug-Resistant Tuberculosis Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 385. Asia Pacific Drug-Resistant Tuberculosis Treatment, by Treatment Type USD Million (2021-2026)
  • Table 386. China Drug-Resistant Tuberculosis Treatment, by Type USD Million (2021-2026)
  • Table 387. China Drug-Resistant Tuberculosis Treatment, by Application USD Million (2021-2026)
  • Table 388. China Drug-Resistant Tuberculosis Treatment, by Disease Type USD Million (2021-2026)
  • Table 389. China Drug-Resistant Tuberculosis Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 390. China Drug-Resistant Tuberculosis Treatment, by Treatment Type USD Million (2021-2026)
  • Table 391. Japan Drug-Resistant Tuberculosis Treatment, by Type USD Million (2021-2026)
  • Table 392. Japan Drug-Resistant Tuberculosis Treatment, by Application USD Million (2021-2026)
  • Table 393. Japan Drug-Resistant Tuberculosis Treatment, by Disease Type USD Million (2021-2026)
  • Table 394. Japan Drug-Resistant Tuberculosis Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 395. Japan Drug-Resistant Tuberculosis Treatment, by Treatment Type USD Million (2021-2026)
  • Table 396. India Drug-Resistant Tuberculosis Treatment, by Type USD Million (2021-2026)
  • Table 397. India Drug-Resistant Tuberculosis Treatment, by Application USD Million (2021-2026)
  • Table 398. India Drug-Resistant Tuberculosis Treatment, by Disease Type USD Million (2021-2026)
  • Table 399. India Drug-Resistant Tuberculosis Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 400. India Drug-Resistant Tuberculosis Treatment, by Treatment Type USD Million (2021-2026)
  • Table 401. South Korea Drug-Resistant Tuberculosis Treatment, by Type USD Million (2021-2026)
  • Table 402. South Korea Drug-Resistant Tuberculosis Treatment, by Application USD Million (2021-2026)
  • Table 403. South Korea Drug-Resistant Tuberculosis Treatment, by Disease Type USD Million (2021-2026)
  • Table 404. South Korea Drug-Resistant Tuberculosis Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 405. South Korea Drug-Resistant Tuberculosis Treatment, by Treatment Type USD Million (2021-2026)
  • Table 406. Taiwan Drug-Resistant Tuberculosis Treatment, by Type USD Million (2021-2026)
  • Table 407. Taiwan Drug-Resistant Tuberculosis Treatment, by Application USD Million (2021-2026)
  • Table 408. Taiwan Drug-Resistant Tuberculosis Treatment, by Disease Type USD Million (2021-2026)
  • Table 409. Taiwan Drug-Resistant Tuberculosis Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 410. Taiwan Drug-Resistant Tuberculosis Treatment, by Treatment Type USD Million (2021-2026)
  • Table 411. Australia Drug-Resistant Tuberculosis Treatment, by Type USD Million (2021-2026)
  • Table 412. Australia Drug-Resistant Tuberculosis Treatment, by Application USD Million (2021-2026)
  • Table 413. Australia Drug-Resistant Tuberculosis Treatment, by Disease Type USD Million (2021-2026)
  • Table 414. Australia Drug-Resistant Tuberculosis Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 415. Australia Drug-Resistant Tuberculosis Treatment, by Treatment Type USD Million (2021-2026)
  • Table 416. Rest of Asia-Pacific Drug-Resistant Tuberculosis Treatment, by Type USD Million (2021-2026)
  • Table 417. Rest of Asia-Pacific Drug-Resistant Tuberculosis Treatment, by Application USD Million (2021-2026)
  • Table 418. Rest of Asia-Pacific Drug-Resistant Tuberculosis Treatment, by Disease Type USD Million (2021-2026)
  • Table 419. Rest of Asia-Pacific Drug-Resistant Tuberculosis Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 420. Rest of Asia-Pacific Drug-Resistant Tuberculosis Treatment, by Treatment Type USD Million (2021-2026)
  • Table 421. Europe Drug-Resistant Tuberculosis Treatment, by Country USD Million (2021-2026)
  • Table 422. Europe Drug-Resistant Tuberculosis Treatment, by Type USD Million (2021-2026)
  • Table 423. Europe Drug-Resistant Tuberculosis Treatment, by Application USD Million (2021-2026)
  • Table 424. Europe Drug-Resistant Tuberculosis Treatment, by Disease Type USD Million (2021-2026)
  • Table 425. Europe Drug-Resistant Tuberculosis Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 426. Europe Drug-Resistant Tuberculosis Treatment, by Treatment Type USD Million (2021-2026)
  • Table 427. Germany Drug-Resistant Tuberculosis Treatment, by Type USD Million (2021-2026)
  • Table 428. Germany Drug-Resistant Tuberculosis Treatment, by Application USD Million (2021-2026)
  • Table 429. Germany Drug-Resistant Tuberculosis Treatment, by Disease Type USD Million (2021-2026)
  • Table 430. Germany Drug-Resistant Tuberculosis Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 431. Germany Drug-Resistant Tuberculosis Treatment, by Treatment Type USD Million (2021-2026)
  • Table 432. France Drug-Resistant Tuberculosis Treatment, by Type USD Million (2021-2026)
  • Table 433. France Drug-Resistant Tuberculosis Treatment, by Application USD Million (2021-2026)
  • Table 434. France Drug-Resistant Tuberculosis Treatment, by Disease Type USD Million (2021-2026)
  • Table 435. France Drug-Resistant Tuberculosis Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 436. France Drug-Resistant Tuberculosis Treatment, by Treatment Type USD Million (2021-2026)
  • Table 437. Italy Drug-Resistant Tuberculosis Treatment, by Type USD Million (2021-2026)
  • Table 438. Italy Drug-Resistant Tuberculosis Treatment, by Application USD Million (2021-2026)
  • Table 439. Italy Drug-Resistant Tuberculosis Treatment, by Disease Type USD Million (2021-2026)
  • Table 440. Italy Drug-Resistant Tuberculosis Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 441. Italy Drug-Resistant Tuberculosis Treatment, by Treatment Type USD Million (2021-2026)
  • Table 442. United Kingdom Drug-Resistant Tuberculosis Treatment, by Type USD Million (2021-2026)
  • Table 443. United Kingdom Drug-Resistant Tuberculosis Treatment, by Application USD Million (2021-2026)
  • Table 444. United Kingdom Drug-Resistant Tuberculosis Treatment, by Disease Type USD Million (2021-2026)
  • Table 445. United Kingdom Drug-Resistant Tuberculosis Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 446. United Kingdom Drug-Resistant Tuberculosis Treatment, by Treatment Type USD Million (2021-2026)
  • Table 447. Netherlands Drug-Resistant Tuberculosis Treatment, by Type USD Million (2021-2026)
  • Table 448. Netherlands Drug-Resistant Tuberculosis Treatment, by Application USD Million (2021-2026)
  • Table 449. Netherlands Drug-Resistant Tuberculosis Treatment, by Disease Type USD Million (2021-2026)
  • Table 450. Netherlands Drug-Resistant Tuberculosis Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 451. Netherlands Drug-Resistant Tuberculosis Treatment, by Treatment Type USD Million (2021-2026)
  • Table 452. Rest of Europe Drug-Resistant Tuberculosis Treatment, by Type USD Million (2021-2026)
  • Table 453. Rest of Europe Drug-Resistant Tuberculosis Treatment, by Application USD Million (2021-2026)
  • Table 454. Rest of Europe Drug-Resistant Tuberculosis Treatment, by Disease Type USD Million (2021-2026)
  • Table 455. Rest of Europe Drug-Resistant Tuberculosis Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 456. Rest of Europe Drug-Resistant Tuberculosis Treatment, by Treatment Type USD Million (2021-2026)
  • Table 457. MEA Drug-Resistant Tuberculosis Treatment, by Country USD Million (2021-2026)
  • Table 458. MEA Drug-Resistant Tuberculosis Treatment, by Type USD Million (2021-2026)
  • Table 459. MEA Drug-Resistant Tuberculosis Treatment, by Application USD Million (2021-2026)
  • Table 460. MEA Drug-Resistant Tuberculosis Treatment, by Disease Type USD Million (2021-2026)
  • Table 461. MEA Drug-Resistant Tuberculosis Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 462. MEA Drug-Resistant Tuberculosis Treatment, by Treatment Type USD Million (2021-2026)
  • Table 463. Middle East Drug-Resistant Tuberculosis Treatment, by Type USD Million (2021-2026)
  • Table 464. Middle East Drug-Resistant Tuberculosis Treatment, by Application USD Million (2021-2026)
  • Table 465. Middle East Drug-Resistant Tuberculosis Treatment, by Disease Type USD Million (2021-2026)
  • Table 466. Middle East Drug-Resistant Tuberculosis Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 467. Middle East Drug-Resistant Tuberculosis Treatment, by Treatment Type USD Million (2021-2026)
  • Table 468. Africa Drug-Resistant Tuberculosis Treatment, by Type USD Million (2021-2026)
  • Table 469. Africa Drug-Resistant Tuberculosis Treatment, by Application USD Million (2021-2026)
  • Table 470. Africa Drug-Resistant Tuberculosis Treatment, by Disease Type USD Million (2021-2026)
  • Table 471. Africa Drug-Resistant Tuberculosis Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 472. Africa Drug-Resistant Tuberculosis Treatment, by Treatment Type USD Million (2021-2026)
  • Table 473. North America Drug-Resistant Tuberculosis Treatment, by Country USD Million (2021-2026)
  • Table 474. North America Drug-Resistant Tuberculosis Treatment, by Type USD Million (2021-2026)
  • Table 475. North America Drug-Resistant Tuberculosis Treatment, by Application USD Million (2021-2026)
  • Table 476. North America Drug-Resistant Tuberculosis Treatment, by Disease Type USD Million (2021-2026)
  • Table 477. North America Drug-Resistant Tuberculosis Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 478. North America Drug-Resistant Tuberculosis Treatment, by Treatment Type USD Million (2021-2026)
  • Table 479. United States Drug-Resistant Tuberculosis Treatment, by Type USD Million (2021-2026)
  • Table 480. United States Drug-Resistant Tuberculosis Treatment, by Application USD Million (2021-2026)
  • Table 481. United States Drug-Resistant Tuberculosis Treatment, by Disease Type USD Million (2021-2026)
  • Table 482. United States Drug-Resistant Tuberculosis Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 483. United States Drug-Resistant Tuberculosis Treatment, by Treatment Type USD Million (2021-2026)
  • Table 484. Canada Drug-Resistant Tuberculosis Treatment, by Type USD Million (2021-2026)
  • Table 485. Canada Drug-Resistant Tuberculosis Treatment, by Application USD Million (2021-2026)
  • Table 486. Canada Drug-Resistant Tuberculosis Treatment, by Disease Type USD Million (2021-2026)
  • Table 487. Canada Drug-Resistant Tuberculosis Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 488. Canada Drug-Resistant Tuberculosis Treatment, by Treatment Type USD Million (2021-2026)
  • Table 489. Mexico Drug-Resistant Tuberculosis Treatment, by Type USD Million (2021-2026)
  • Table 490. Mexico Drug-Resistant Tuberculosis Treatment, by Application USD Million (2021-2026)
  • Table 491. Mexico Drug-Resistant Tuberculosis Treatment, by Disease Type USD Million (2021-2026)
  • Table 492. Mexico Drug-Resistant Tuberculosis Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 493. Mexico Drug-Resistant Tuberculosis Treatment, by Treatment Type USD Million (2021-2026)
  • Table 494. Drug-Resistant Tuberculosis Treatment Sales: by Type(K Units)
  • Table 495. Drug-Resistant Tuberculosis Treatment Sales Amoxicillin/Clavulanate , by Region K Units (2021-2026)
  • Table 496. Drug-Resistant Tuberculosis Treatment Sales Bedaquiline , by Region K Units (2021-2026)
  • Table 497. Drug-Resistant Tuberculosis Treatment Sales Carbapenems with Clavulanic Acid , by Region K Units (2021-2026)
  • Table 498. Drug-Resistant Tuberculosis Treatment Sales Clofazimine , by Region K Units (2021-2026)
  • Table 499. Drug-Resistant Tuberculosis Treatment Sales Cycloserine , by Region K Units (2021-2026)
  • Table 500. Drug-Resistant Tuberculosis Treatment Sales Delamanid , by Region K Units (2021-2026)
  • Table 501. Drug-Resistant Tuberculosis Treatment Sales Ethambutol , by Region K Units (2021-2026)
  • Table 502. Drug-Resistant Tuberculosis Treatment Sales Others , by Region K Units (2021-2026)
  • Table 503. Drug-Resistant Tuberculosis Treatment Sales: by Application(K Units)
  • Table 504. Drug-Resistant Tuberculosis Treatment Sales Hospital , by Region K Units (2021-2026)
  • Table 505. Drug-Resistant Tuberculosis Treatment Sales Clinics , by Region K Units (2021-2026)
  • Table 506. Drug-Resistant Tuberculosis Treatment Sales Others , by Region K Units (2021-2026)
  • Table 507. Drug-Resistant Tuberculosis Treatment Sales: by Disease Type(K Units)
  • Table 508. Drug-Resistant Tuberculosis Treatment Sales Multidrug-Resistant TB (MDR TB) , by Region K Units (2021-2026)
  • Table 509. Drug-Resistant Tuberculosis Treatment Sales Extensively Drug-resistant TB (XDR TB) , by Region K Units (2021-2026)
  • Table 510. Drug-Resistant Tuberculosis Treatment Sales: by Distribution Channel(K Units)
  • Table 511. Drug-Resistant Tuberculosis Treatment Sales Hospital Pharmacy , by Region K Units (2021-2026)
  • Table 512. Drug-Resistant Tuberculosis Treatment Sales Online Pharmacy , by Region K Units (2021-2026)
  • Table 513. Drug-Resistant Tuberculosis Treatment Sales Retail Pharmacy , by Region K Units (2021-2026)
  • Table 514. Drug-Resistant Tuberculosis Treatment Sales Others , by Region K Units (2021-2026)
  • Table 515. Drug-Resistant Tuberculosis Treatment Sales: by Treatment Type(K Units)
  • Table 516. Drug-Resistant Tuberculosis Treatment Sales First-Line Anti-TB Drugs , by Region K Units (2021-2026)
  • Table 517. Drug-Resistant Tuberculosis Treatment Sales Second-Line Anti-TB Drugs , by Region K Units (2021-2026)
  • Table 518. Drug-Resistant Tuberculosis Treatment Sales Others , by Region K Units (2021-2026)
  • Table 519. South America Drug-Resistant Tuberculosis Treatment Sales, by Country K Units (2021-2026)
  • Table 520. South America Drug-Resistant Tuberculosis Treatment Sales, by Type K Units (2021-2026)
  • Table 521. South America Drug-Resistant Tuberculosis Treatment Sales, by Application K Units (2021-2026)
  • Table 522. South America Drug-Resistant Tuberculosis Treatment Sales, by Disease Type K Units (2021-2026)
  • Table 523. South America Drug-Resistant Tuberculosis Treatment Sales, by Distribution Channel K Units (2021-2026)
  • Table 524. South America Drug-Resistant Tuberculosis Treatment Sales, by Treatment Type K Units (2021-2026)
  • Table 525. Brazil Drug-Resistant Tuberculosis Treatment Sales, by Type K Units (2021-2026)
  • Table 526. Brazil Drug-Resistant Tuberculosis Treatment Sales, by Application K Units (2021-2026)
  • Table 527. Brazil Drug-Resistant Tuberculosis Treatment Sales, by Disease Type K Units (2021-2026)
  • Table 528. Brazil Drug-Resistant Tuberculosis Treatment Sales, by Distribution Channel K Units (2021-2026)
  • Table 529. Brazil Drug-Resistant Tuberculosis Treatment Sales, by Treatment Type K Units (2021-2026)
  • Table 530. Argentina Drug-Resistant Tuberculosis Treatment Sales, by Type K Units (2021-2026)
  • Table 531. Argentina Drug-Resistant Tuberculosis Treatment Sales, by Application K Units (2021-2026)
  • Table 532. Argentina Drug-Resistant Tuberculosis Treatment Sales, by Disease Type K Units (2021-2026)
  • Table 533. Argentina Drug-Resistant Tuberculosis Treatment Sales, by Distribution Channel K Units (2021-2026)
  • Table 534. Argentina Drug-Resistant Tuberculosis Treatment Sales, by Treatment Type K Units (2021-2026)
  • Table 535. Rest of South America Drug-Resistant Tuberculosis Treatment Sales, by Type K Units (2021-2026)
  • Table 536. Rest of South America Drug-Resistant Tuberculosis Treatment Sales, by Application K Units (2021-2026)
  • Table 537. Rest of South America Drug-Resistant Tuberculosis Treatment Sales, by Disease Type K Units (2021-2026)
  • Table 538. Rest of South America Drug-Resistant Tuberculosis Treatment Sales, by Distribution Channel K Units (2021-2026)
  • Table 539. Rest of South America Drug-Resistant Tuberculosis Treatment Sales, by Treatment Type K Units (2021-2026)
  • Table 540. Asia Pacific Drug-Resistant Tuberculosis Treatment Sales, by Country K Units (2021-2026)
  • Table 541. Asia Pacific Drug-Resistant Tuberculosis Treatment Sales, by Type K Units (2021-2026)
  • Table 542. Asia Pacific Drug-Resistant Tuberculosis Treatment Sales, by Application K Units (2021-2026)
  • Table 543. Asia Pacific Drug-Resistant Tuberculosis Treatment Sales, by Disease Type K Units (2021-2026)
  • Table 544. Asia Pacific Drug-Resistant Tuberculosis Treatment Sales, by Distribution Channel K Units (2021-2026)
  • Table 545. Asia Pacific Drug-Resistant Tuberculosis Treatment Sales, by Treatment Type K Units (2021-2026)
  • Table 546. China Drug-Resistant Tuberculosis Treatment Sales, by Type K Units (2021-2026)
  • Table 547. China Drug-Resistant Tuberculosis Treatment Sales, by Application K Units (2021-2026)
  • Table 548. China Drug-Resistant Tuberculosis Treatment Sales, by Disease Type K Units (2021-2026)
  • Table 549. China Drug-Resistant Tuberculosis Treatment Sales, by Distribution Channel K Units (2021-2026)
  • Table 550. China Drug-Resistant Tuberculosis Treatment Sales, by Treatment Type K Units (2021-2026)
  • Table 551. Japan Drug-Resistant Tuberculosis Treatment Sales, by Type K Units (2021-2026)
  • Table 552. Japan Drug-Resistant Tuberculosis Treatment Sales, by Application K Units (2021-2026)
  • Table 553. Japan Drug-Resistant Tuberculosis Treatment Sales, by Disease Type K Units (2021-2026)
  • Table 554. Japan Drug-Resistant Tuberculosis Treatment Sales, by Distribution Channel K Units (2021-2026)
  • Table 555. Japan Drug-Resistant Tuberculosis Treatment Sales, by Treatment Type K Units (2021-2026)
  • Table 556. India Drug-Resistant Tuberculosis Treatment Sales, by Type K Units (2021-2026)
  • Table 557. India Drug-Resistant Tuberculosis Treatment Sales, by Application K Units (2021-2026)
  • Table 558. India Drug-Resistant Tuberculosis Treatment Sales, by Disease Type K Units (2021-2026)
  • Table 559. India Drug-Resistant Tuberculosis Treatment Sales, by Distribution Channel K Units (2021-2026)
  • Table 560. India Drug-Resistant Tuberculosis Treatment Sales, by Treatment Type K Units (2021-2026)
  • Table 561. South Korea Drug-Resistant Tuberculosis Treatment Sales, by Type K Units (2021-2026)
  • Table 562. South Korea Drug-Resistant Tuberculosis Treatment Sales, by Application K Units (2021-2026)
  • Table 563. South Korea Drug-Resistant Tuberculosis Treatment Sales, by Disease Type K Units (2021-2026)
  • Table 564. South Korea Drug-Resistant Tuberculosis Treatment Sales, by Distribution Channel K Units (2021-2026)
  • Table 565. South Korea Drug-Resistant Tuberculosis Treatment Sales, by Treatment Type K Units (2021-2026)
  • Table 566. Taiwan Drug-Resistant Tuberculosis Treatment Sales, by Type K Units (2021-2026)
  • Table 567. Taiwan Drug-Resistant Tuberculosis Treatment Sales, by Application K Units (2021-2026)
  • Table 568. Taiwan Drug-Resistant Tuberculosis Treatment Sales, by Disease Type K Units (2021-2026)
  • Table 569. Taiwan Drug-Resistant Tuberculosis Treatment Sales, by Distribution Channel K Units (2021-2026)
  • Table 570. Taiwan Drug-Resistant Tuberculosis Treatment Sales, by Treatment Type K Units (2021-2026)
  • Table 571. Australia Drug-Resistant Tuberculosis Treatment Sales, by Type K Units (2021-2026)
  • Table 572. Australia Drug-Resistant Tuberculosis Treatment Sales, by Application K Units (2021-2026)
  • Table 573. Australia Drug-Resistant Tuberculosis Treatment Sales, by Disease Type K Units (2021-2026)
  • Table 574. Australia Drug-Resistant Tuberculosis Treatment Sales, by Distribution Channel K Units (2021-2026)
  • Table 575. Australia Drug-Resistant Tuberculosis Treatment Sales, by Treatment Type K Units (2021-2026)
  • Table 576. Rest of Asia-Pacific Drug-Resistant Tuberculosis Treatment Sales, by Type K Units (2021-2026)
  • Table 577. Rest of Asia-Pacific Drug-Resistant Tuberculosis Treatment Sales, by Application K Units (2021-2026)
  • Table 578. Rest of Asia-Pacific Drug-Resistant Tuberculosis Treatment Sales, by Disease Type K Units (2021-2026)
  • Table 579. Rest of Asia-Pacific Drug-Resistant Tuberculosis Treatment Sales, by Distribution Channel K Units (2021-2026)
  • Table 580. Rest of Asia-Pacific Drug-Resistant Tuberculosis Treatment Sales, by Treatment Type K Units (2021-2026)
  • Table 581. Europe Drug-Resistant Tuberculosis Treatment Sales, by Country K Units (2021-2026)
  • Table 582. Europe Drug-Resistant Tuberculosis Treatment Sales, by Type K Units (2021-2026)
  • Table 583. Europe Drug-Resistant Tuberculosis Treatment Sales, by Application K Units (2021-2026)
  • Table 584. Europe Drug-Resistant Tuberculosis Treatment Sales, by Disease Type K Units (2021-2026)
  • Table 585. Europe Drug-Resistant Tuberculosis Treatment Sales, by Distribution Channel K Units (2021-2026)
  • Table 586. Europe Drug-Resistant Tuberculosis Treatment Sales, by Treatment Type K Units (2021-2026)
  • Table 587. Germany Drug-Resistant Tuberculosis Treatment Sales, by Type K Units (2021-2026)
  • Table 588. Germany Drug-Resistant Tuberculosis Treatment Sales, by Application K Units (2021-2026)
  • Table 589. Germany Drug-Resistant Tuberculosis Treatment Sales, by Disease Type K Units (2021-2026)
  • Table 590. Germany Drug-Resistant Tuberculosis Treatment Sales, by Distribution Channel K Units (2021-2026)
  • Table 591. Germany Drug-Resistant Tuberculosis Treatment Sales, by Treatment Type K Units (2021-2026)
  • Table 592. France Drug-Resistant Tuberculosis Treatment Sales, by Type K Units (2021-2026)
  • Table 593. France Drug-Resistant Tuberculosis Treatment Sales, by Application K Units (2021-2026)
  • Table 594. France Drug-Resistant Tuberculosis Treatment Sales, by Disease Type K Units (2021-2026)
  • Table 595. France Drug-Resistant Tuberculosis Treatment Sales, by Distribution Channel K Units (2021-2026)
  • Table 596. France Drug-Resistant Tuberculosis Treatment Sales, by Treatment Type K Units (2021-2026)
  • Table 597. Italy Drug-Resistant Tuberculosis Treatment Sales, by Type K Units (2021-2026)
  • Table 598. Italy Drug-Resistant Tuberculosis Treatment Sales, by Application K Units (2021-2026)
  • Table 599. Italy Drug-Resistant Tuberculosis Treatment Sales, by Disease Type K Units (2021-2026)
  • Table 600. Italy Drug-Resistant Tuberculosis Treatment Sales, by Distribution Channel K Units (2021-2026)
  • Table 601. Italy Drug-Resistant Tuberculosis Treatment Sales, by Treatment Type K Units (2021-2026)
  • Table 602. United Kingdom Drug-Resistant Tuberculosis Treatment Sales, by Type K Units (2021-2026)
  • Table 603. United Kingdom Drug-Resistant Tuberculosis Treatment Sales, by Application K Units (2021-2026)
  • Table 604. United Kingdom Drug-Resistant Tuberculosis Treatment Sales, by Disease Type K Units (2021-2026)
  • Table 605. United Kingdom Drug-Resistant Tuberculosis Treatment Sales, by Distribution Channel K Units (2021-2026)
  • Table 606. United Kingdom Drug-Resistant Tuberculosis Treatment Sales, by Treatment Type K Units (2021-2026)
  • Table 607. Netherlands Drug-Resistant Tuberculosis Treatment Sales, by Type K Units (2021-2026)
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Drug-Resistant Tuberculosis Treatment: by Type USD Million (2015-2020)
  • Figure 5. Global Drug-Resistant Tuberculosis Treatment: by Application USD Million (2015-2020)
  • Figure 6. Global Drug-Resistant Tuberculosis Treatment: by Disease Type USD Million (2015-2020)
  • Figure 7. Global Drug-Resistant Tuberculosis Treatment: by Distribution Channel USD Million (2015-2020)
  • Figure 8. Global Drug-Resistant Tuberculosis Treatment: by Treatment Type USD Million (2015-2020)
  • Figure 9. South America Drug-Resistant Tuberculosis Treatment Share (%), by Country
  • Figure 10. Asia Pacific Drug-Resistant Tuberculosis Treatment Share (%), by Country
  • Figure 11. Europe Drug-Resistant Tuberculosis Treatment Share (%), by Country
  • Figure 12. MEA Drug-Resistant Tuberculosis Treatment Share (%), by Country
  • Figure 13. North America Drug-Resistant Tuberculosis Treatment Share (%), by Country
  • Figure 14. Global Drug-Resistant Tuberculosis Treatment: by Type K Units (2015-2020)
  • Figure 15. Global Drug-Resistant Tuberculosis Treatment: by Application K Units (2015-2020)
  • Figure 16. Global Drug-Resistant Tuberculosis Treatment: by Disease Type K Units (2015-2020)
  • Figure 17. Global Drug-Resistant Tuberculosis Treatment: by Distribution Channel K Units (2015-2020)
  • Figure 18. Global Drug-Resistant Tuberculosis Treatment: by Treatment Type K Units (2015-2020)
  • Figure 19. South America Drug-Resistant Tuberculosis Treatment Share (%), by Country
  • Figure 20. Asia Pacific Drug-Resistant Tuberculosis Treatment Share (%), by Country
  • Figure 21. Europe Drug-Resistant Tuberculosis Treatment Share (%), by Country
  • Figure 22. MEA Drug-Resistant Tuberculosis Treatment Share (%), by Country
  • Figure 23. North America Drug-Resistant Tuberculosis Treatment Share (%), by Country
  • Figure 24. Global Drug-Resistant Tuberculosis Treatment: by Type USD/Units (2015-2020)
  • Figure 25. Global Drug-Resistant Tuberculosis Treatment share by Players 2020 (%)
  • Figure 26. Global Drug-Resistant Tuberculosis Treatment share by Players (Top 3) 2020(%)
  • Figure 27. Global Drug-Resistant Tuberculosis Treatment share by Players (Top 5) 2020(%)
  • Figure 28. BCG Matrix for key Companies
  • Figure 29. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 30. Sanofi (France) Revenue: by Geography 2020
  • Figure 31. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 32. Novartis AG (Switzerland) Revenue: by Geography 2020
  • Figure 33. Endo International plc (Ireland) Revenue, Net Income and Gross profit
  • Figure 34. Endo International plc (Ireland) Revenue: by Geography 2020
  • Figure 35. CMP Pharma (United States) Revenue, Net Income and Gross profit
  • Figure 36. CMP Pharma (United States) Revenue: by Geography 2020
  • Figure 37. STI Pharma LLC (United States) Revenue, Net Income and Gross profit
  • Figure 38. STI Pharma LLC (United States) Revenue: by Geography 2020
  • Figure 39. Akorn Incorporated (United States) Revenue, Net Income and Gross profit
  • Figure 40. Akorn Incorporated (United States) Revenue: by Geography 2020
  • Figure 41. Lupin (India) Revenue, Net Income and Gross profit
  • Figure 42. Lupin (India) Revenue: by Geography 2020
  • Figure 43. Johnson & Johnson Services Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 44. Johnson & Johnson Services Inc. (United States) Revenue: by Geography 2020
  • Figure 45. Macleods Pharmaceuticals Ltd (India) Revenue, Net Income and Gross profit
  • Figure 46. Macleods Pharmaceuticals Ltd (India) Revenue: by Geography 2020
  • Figure 47. Pfizer Inc (United States) Revenue, Net Income and Gross profit
  • Figure 48. Pfizer Inc (United States) Revenue: by Geography 2020
  • Figure 49. Hikma Pharmaceuticals PLC (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 50. Hikma Pharmaceuticals PLC (United Kingdom) Revenue: by Geography 2020
  • Figure 51. Lannett (United States) Revenue, Net Income and Gross profit
  • Figure 52. Lannett (United States) Revenue: by Geography 2020
  • Figure 53. Global Drug-Resistant Tuberculosis Treatment: by Type USD Million (2021-2026)
  • Figure 54. Global Drug-Resistant Tuberculosis Treatment: by Application USD Million (2021-2026)
  • Figure 55. Global Drug-Resistant Tuberculosis Treatment: by Disease Type USD Million (2021-2026)
  • Figure 56. Global Drug-Resistant Tuberculosis Treatment: by Distribution Channel USD Million (2021-2026)
  • Figure 57. Global Drug-Resistant Tuberculosis Treatment: by Treatment Type USD Million (2021-2026)
  • Figure 58. South America Drug-Resistant Tuberculosis Treatment Share (%), by Country
  • Figure 59. Asia Pacific Drug-Resistant Tuberculosis Treatment Share (%), by Country
  • Figure 60. Europe Drug-Resistant Tuberculosis Treatment Share (%), by Country
  • Figure 61. MEA Drug-Resistant Tuberculosis Treatment Share (%), by Country
  • Figure 62. North America Drug-Resistant Tuberculosis Treatment Share (%), by Country
  • Figure 63. Global Drug-Resistant Tuberculosis Treatment: by Type K Units (2021-2026)
  • Figure 64. Global Drug-Resistant Tuberculosis Treatment: by Application K Units (2021-2026)
  • Figure 65. Global Drug-Resistant Tuberculosis Treatment: by Disease Type K Units (2021-2026)
  • Figure 66. Global Drug-Resistant Tuberculosis Treatment: by Distribution Channel K Units (2021-2026)
  • Figure 67. Global Drug-Resistant Tuberculosis Treatment: by Treatment Type K Units (2021-2026)
  • Figure 68. South America Drug-Resistant Tuberculosis Treatment Share (%), by Country
  • Figure 69. Asia Pacific Drug-Resistant Tuberculosis Treatment Share (%), by Country
  • Figure 70. Europe Drug-Resistant Tuberculosis Treatment Share (%), by Country
  • Figure 71. MEA Drug-Resistant Tuberculosis Treatment Share (%), by Country
  • Figure 72. North America Drug-Resistant Tuberculosis Treatment Share (%), by Country
  • Figure 73. Global Drug-Resistant Tuberculosis Treatment: by Type USD/Units (2021-2026)
Some of the key companies/manufacturers profiled in the report
  • Sanofi (France)
  • Novartis AG (Switzerland)
  • Endo International plc (Ireland)
  • CMP Pharma (United States)
  • STI Pharma LLC (United States)
  • Akorn Incorporated (United States)
  • Lupin (India)
  • Johnson & Johnson Services Inc. (United States)
  • Macleods Pharmaceuticals Ltd (India)
  • Pfizer Inc (United States)
  • Hikma Pharmaceuticals PLC (United Kingdom)
  • Lannett (United States)
Additional players considered in the study are as follows:
Mylan N.V. (United States) , Teva Pharmaceutical Industries Ltd (Israel) , Fresenius Kabi AG (Germany)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation